The treatment, Dupixent, was approved May 20 to treat eosinophilic esophagitis in adults and pediatric patients 12 and older weighing at least 88 pounds.
Dupixent is a monoclonal antibody that helps stop part of the inflammatory pathway of the esophagus in those with the disease, the release said.
